AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004, was well tolerated by patients in an early-stage ...

Investors need to pay close attention to AstraZeneca (AZN) stock based on the movements in the options market lately.

The pharmaceutical giant, whose China chief is now under investigation, was previously at the centre of insurance scam cases, ...

AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety ...

China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

The AstraZeneca PLC ADR AZN inched 0.01% higher to $71.43 Monday, on what proved to be an all-around grim trading session for ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

UBS analyst Matthew Weston maintained a Sell rating on AstraZeneca (AZN – Research Report) today and set a price target of £113.00. The ...